All News
Pregnancy Updates That Will Change The Way I Practice
ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification.
Read Article
Towards Personalised Care in Rheumatoid Arthritis
Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs for rheumatoid arthritis. The challenge remains on how best to characterise the subtypes of RA in order to choose the best drug to ensure optimal outcome for patients.
Read Article
Takeaways from #ACR23 #ReviewCourse session on Systemic Sclerosis Screening for Organ Involvement - Dr. Francesco Boin
1. Always approach SSc as a systemic disease (see slide). Survival is determined by subset (limited vs diffuse) and organ manifestations.
2. Autoantibodies… https://t.co/TmrPqLJYzD https://t.co/ajHDVpUbhO
Paul Sufka, MD psufka ( View Tweet)
Axial PsA or AS? #ACR23 Abs #0492 finds age > 45 at LBP onset, female sex, higher frequency of PsO, and shorter time to dx may be better predictors of axial PsA. https://t.co/3sEj8NxtzP @rheumnow https://t.co/nV7NHk7WtD
Dr. Rachel Tate ( View Tweet)
Deucravacitinib tx found to have comparable effects on PsA disease activity and PROs after 16 weeks in both male and female patients. #ACR23 Abs 0485 https://t.co/w36rX3B77K @rheumnow https://t.co/q41ioJDMML
Dr. Rachel Tate ( View Tweet)
Racial/ethnic minority PsA pts less likely to be diagnosed w/in 12 mos from symptom onset (50% vs 71%; P < 0.001) and more frequently uninsured (8% vs. 1%; P < 0.001) compared to white pts. #ACR23 Abs #0490 https://t.co/MKO9hblGYT @rheumnow https://t.co/K8GgkhHOqw
Dr. Rachel Tate ( View Tweet)
In bDMARD-IR AS patients, UPA led to numerically greater improvements vs PBO in physical activity as measured by a wearable device over 14 wks, especially in sedentary patients. #ACR23 Abs #0530 https://t.co/6Me2XctK6D @rheumnow https://t.co/c6E2GfAGt4
Dr. Rachel Tate ( View Tweet)
Large Chicago study Abs #0535 at #ACR23 biologic tx prescribed more often for males, Non-Hispanic Blacks and Latinx in AS. Low SES, measured by SDI, and insurance status did not affect if pt received bDMARD. https://t.co/MdDuNPMCC9 @rheumnow https://t.co/Oa9aC3rbb0
Dr. Rachel Tate ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
Following on from the #ACR23 keynote, a deeper dive on how AI might actually help clinical rheumatologists in real life, from clinical rheumatologist @DrCMcMaster @DT4Health et al in @ACR_Journals:
https://t.co/dQJzTwScy0
@RheumNow
David Liew drdavidliew ( View Tweet)
#ACR23 Abs #0505 found use of IL-17 inhibitors and oral DMARD alone were associated with a decreased likelihood of achieving MDA in PsA. Small sample size, but interesting finding nonetheless. https://t.co/CAZGykwxRT @rheumnow https://t.co/8ptF8aTIFu
Dr. Rachel Tate ( View Tweet)
💡RP is a heterogeneous disease.
💡Think VEXAS in RP with MDS.
💡Think MAGIC if oral/genital ulcers.
💡Pts are experts on their own disease! Listen and acknowledge their symptoms. Shout out to Dr @maferradastrong
#ACR23 #ImNotYellingImColombian🇨🇴
@ACRheum @RheumNow https://t.co/nTZ96pJh09
Adela Castro AdelaCastro222 ( View Tweet)
💡Screen pts with Ssc for ILD with HRCT at diagnosis.
💡“MCTD” may meet criteria for Ssc dont look away at the positive U1RNP!
💡Kidney biopsy in SRC =Time is of the essence.
💡Cardiac involvement is 2nd cause of mortality screen with echo annually. @fboinMD #ACR23 @RheumNow https://t.co/yp3yjqqeQv
Adela Castro AdelaCastro222 ( View Tweet)
How can we maximise digital health to improve outcomes. Come and visit my poster session today and it will be good to meet IRL. I’m presenting poster #0507 using digital e-PROMs to measure disease activity in psoriatic arthritis #digital Abst #0507 #ACR23 @RheumNow https://t.co/R9LX8H9X0E
Dr. Antoni Chan ( View Tweet)
#ACR23 Abs 0484 found higher hs-CRP levels helped identify PsO pts at high risk of future development of PsA. Unclear timeline, but this may help to early ID referrals to rheum. https://t.co/4JRsI6iEgI @rheumnow https://t.co/sXNwyL87Ud
Dr. Rachel Tate ( View Tweet)
Pain, itch, and fatigue associated with decreased work productivity/impairment in PsA and PsO pts. #ACR23 considerations for treatment for these pts should include these factors. Abs #0488 https://t.co/mLG5ohFopQ @rheumnow https://t.co/8ANL4pcxM2
Dr. Rachel Tate ( View Tweet)
#ACR23 Abstr#PP12 "I am stronger than my disease & won’t let it stop me from leading a fulfilling life!"- a person with #Sjogren shared tips on lifestyle modification to help fatigue.
- schedule appointments in the morning
- exercise
- keep a diary
- listen to body
@RheumNow https://t.co/8ROFrDvPS1
Md Yuzaiful Md Yusof ( View Tweet)
Do you check fecal calprotectin levels in your SpA pts? Maybe you should. #ACR23 Abs #0495 EISER study shows increased prevalence of undiagnosed IBD in SpA that may be detected in our clinics with fecal calprotectin levels prior to GI evaluation. https://t.co/d7BbrUd570 @rheumnow https://t.co/COcKdvjWnr
Dr. Rachel Tate ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
AI is here to stay, like it or not.
Some words to ponder on👇
#ACR23 @RheumNow @rheumarhyme https://t.co/2K3Qc0Il8i
sheila ( View Tweet)